Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/SCYL2_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/SCYL2_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/SCYL2_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/SCYL2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/SCYL2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/SCYL2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/SCYL2_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/SCYL2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00431124 | Liver | NAFLD | receptor metabolic process | 31/1882 | 166/18723 | 5.10e-04 | 7.15e-03 | 31 |
GO:00482594 | Liver | NAFLD | regulation of receptor-mediated endocytosis | 23/1882 | 110/18723 | 5.16e-04 | 7.15e-03 | 23 |
GO:00725834 | Liver | NAFLD | clathrin-dependent endocytosis | 13/1882 | 47/18723 | 5.46e-04 | 7.45e-03 | 13 |
GO:00070345 | Liver | NAFLD | vacuolar transport | 28/1882 | 157/18723 | 1.91e-03 | 1.93e-02 | 28 |
GO:00070414 | Liver | NAFLD | lysosomal transport | 22/1882 | 114/18723 | 2.03e-03 | 2.02e-02 | 22 |
GO:00301005 | Liver | NAFLD | regulation of endocytosis | 35/1882 | 211/18723 | 2.09e-03 | 2.06e-02 | 35 |
GO:000703421 | Liver | HCC | vacuolar transport | 108/7958 | 157/18723 | 2.22e-11 | 8.69e-10 | 108 |
GO:019873821 | Liver | HCC | cell-cell signaling by wnt | 247/7958 | 446/18723 | 2.11e-08 | 4.96e-07 | 247 |
GO:001605521 | Liver | HCC | Wnt signaling pathway | 245/7958 | 444/18723 | 3.68e-08 | 8.09e-07 | 245 |
GO:000704121 | Liver | HCC | lysosomal transport | 76/7958 | 114/18723 | 1.56e-07 | 2.88e-06 | 76 |
GO:003011121 | Liver | HCC | regulation of Wnt signaling pathway | 180/7958 | 328/18723 | 3.62e-06 | 4.72e-05 | 180 |
GO:004311221 | Liver | HCC | receptor metabolic process | 96/7958 | 166/18723 | 4.69e-05 | 4.50e-04 | 96 |
GO:000689821 | Liver | HCC | receptor-mediated endocytosis | 134/7958 | 244/18723 | 5.73e-05 | 5.31e-04 | 134 |
GO:006007021 | Liver | HCC | canonical Wnt signaling pathway | 162/7958 | 303/18723 | 7.00e-05 | 6.32e-04 | 162 |
GO:003010021 | Liver | HCC | regulation of endocytosis | 117/7958 | 211/18723 | 9.56e-05 | 8.32e-04 | 117 |
GO:006082821 | Liver | HCC | regulation of canonical Wnt signaling pathway | 137/7958 | 253/18723 | 1.15e-04 | 9.70e-04 | 137 |
GO:004580721 | Liver | HCC | positive regulation of endocytosis | 59/7958 | 100/18723 | 6.35e-04 | 3.93e-03 | 59 |
GO:007258311 | Liver | HCC | clathrin-dependent endocytosis | 31/7958 | 47/18723 | 9.90e-04 | 5.71e-03 | 31 |
GO:00083331 | Liver | HCC | endosome to lysosome transport | 35/7958 | 55/18723 | 1.26e-03 | 6.92e-03 | 35 |
GO:004825921 | Liver | HCC | regulation of receptor-mediated endocytosis | 60/7958 | 110/18723 | 7.12e-03 | 2.84e-02 | 60 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SCYL2 | SNV | Missense_Mutation | novel | c.416N>G | p.Pro139Arg | p.P139R | | protein_coding | deleterious(0.01) | benign(0.285) | TCGA-A2-A04Q-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
SCYL2 | SNV | Missense_Mutation | novel | c.1571N>G | p.Asp524Gly | p.D524G | | protein_coding | deleterious(0) | probably_damaging(0.952) | TCGA-A8-A085-01 | Breast | breast invasive carcinoma | Male | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
SCYL2 | SNV | Missense_Mutation | | c.834N>A | p.Phe278Leu | p.F278L | | protein_coding | tolerated(0.09) | benign(0.32) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
SCYL2 | SNV | Missense_Mutation | rs147018741 | c.1525N>T | p.Arg509Cys | p.R509C | | protein_coding | deleterious(0) | benign(0.432) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SCYL2 | SNV | Missense_Mutation | | c.2698A>T | p.Met900Leu | p.M900L | | protein_coding | tolerated_low_confidence(0.28) | benign(0) | TCGA-B6-A1KN-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
SCYL2 | SNV | Missense_Mutation | novel | c.628N>C | p.Glu210Gln | p.E210Q | | protein_coding | tolerated(0.54) | benign(0.025) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SCYL2 | SNV | Missense_Mutation | novel | c.2525C>T | p.Ser842Phe | p.S842F | | protein_coding | deleterious(0) | probably_damaging(0.979) | TCGA-BH-A0H5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR |
SCYL2 | SNV | Missense_Mutation | | c.2022N>C | p.Gln674His | p.Q674H | | protein_coding | tolerated(0.13) | benign(0.003) | TCGA-D8-A147-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine | SD |
SCYL2 | SNV | Missense_Mutation | | c.958C>G | p.Gln320Glu | p.Q320E | | protein_coding | tolerated(0.16) | possibly_damaging(0.55) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
SCYL2 | SNV | Missense_Mutation | novel | c.1343A>G | p.Glu448Gly | p.E448G | | protein_coding | tolerated(0.06) | benign(0.042) | TCGA-D8-A3Z6-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphane | SD |